Phase III
Boehringer Ingelheim and Eli Lilly and Company announced that the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, met the primary endpoint.
Atogepant, an oral CGRP receptor antagonist, is an experimental migraine treatment AbbVie gained through its acquisition of Allergan.
Roche’s Actemra failed to meet its primary and secondary endpoints in a late-stage study involving hospitalized patients with severe COVID-19 associated pneumonia.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 29, 2020.
AstraZeneca reported successful results from its Phase III DAPA-CKD clinical trial of Farxiga (dapagliflozin) in end stage kidney disease (ESKD).
The vaccine will be dosed at a 30-microgram level with a two-dose regimen. The vaccine is an mRNA product, with the mRNA encoding for the SARS-CoV-2 full length spike glycoprotein (S).
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 27, 2020.
It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Jakafi hit the mark, meeting the trial’s primary endpoint of superior overall response rate (ORR) at Week 24 compared to best available therapy (BAT).
PRESS RELEASES